NorthShore University HealthSystem
Evanston, Illinois, 60201, United States
NCT Number: NCT03860519
This is a behavioral randomized controlled trial of adults with uncontrolled persistent asthma that tests if the Propeller Health sensor, mobile application, and dashboard can improve adherence to ICS.
Looking for future studies?
Notify Me25 year–65 year
All sexes
Interventional
Not applicable
Evanston, Illinois, 60201, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The patients in the intervention group will have sensors that are "active", so that these patients receive reminders about when to use their inhalers medications.
Other names: MDI, Diskus
The patients in the control group will have sensors that are "silent", so that these patients do not receive reminders about when to use their inhalers medications.
Other names: MDI, Diskus
Patients in the intervention group will have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
Patients in the control group will not have access to their medication usage information (as collected by their sensors) via their Propeller Health applications.
Patients in the intervention will receive feedback from the Research Nurse about their medication use and asthma control status.
Patients in the intervention will not receive feedback from the Research Nurse about their medication use and asthma control status.
Patients in the intervention group will receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
Patients in the control group will not receive monthly calls from the Research Nurse to obtain feedback information about the Propeller Health Platform.
Time frame: 3.5 months
Use of the Propeller Health Platform in the treatment group in active mode, compared to the attention control group in silent mode, will demonstrate a 20% change in SABA use and/or minimal clinically important difference (three points) change on the ACT and/or change from ACT score ≤ 19 to ≥20, at 3-months. The 20% change in SABA use = 20 point change (e.g. if a participants uses SABA 40% of days over the 2 week run-in period, and they change SABA use to 20% of days during the final 14 days of the active treatment period, that will equal a 20 point change. If SABA use changes from 40% of days over the 2- week run-in period to 32% of days during the final 14 days of the active treatment period, this will not be considered a 20 point change).
Time frame: 3.5 months
Study staff developed a brief survey using open-ended questions (i.e. 20 questions, no scales used, no minimum or maximum scores are applicable) to ask participants and clinicians whether they were satisfied using the Propeller Health Platform Digital Technology. Standardized instruments are not being used.
Time frame: 3 months
To determine if two Propeller Health Platform Digital Technology arms (i.e. Arm #1= Technology in active "on" mode and Arm #2= Technology in passive "off" mode) demonstrate a change in inhaled corticosteroid medication taking behavior at 3 months.
Endeavor Health
Other
The Use of the Propeller Health Platform to Improve Inhaled Corticosteroid (ICS) Use Among Adults With Uncontrolled Persistent Asthma (Propeller Health)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07746570
Asthma, Bronchial Diseases
Erzincan, Merkez, Turkey (Türkiye)
View Trial DetailsNCT03937804
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT00001888
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06290102
Asthma, Bronchial Diseases
Mobile, Alabama, United States
View Trial Details